Developments in the lung cancer market over the next 12 months will be crucial to the future of beleaguered Bristol-Myers Squibb Co. and help investors determine whether shareholder value – and thus satisfaction with its management – can be unlocked, or whether activists, which include Carl Icahn and JANA Partners, will instead push for quicker profits via a rival takeover of the company worth more than $100bn.
That's the current view of many analysts and investors who are trying to make sense of BMS' situation following months of uncertainty, a sagging share price following PD-1 inhibitor Opdivo's...
